Long-Term Outcomes Of Ruxolitinib (Rux) Therapy In Patients (Pts) With Myelofibrosis (Mf): 5-Year Update From Comfort-I.
JOURNAL OF CLINICAL ONCOLOGY（2016）
摘要
7012Background: The JAK1/JAK2 inhibitor RUX has demonstrated rapid and durable improvements in splenomegaly and symptoms and improved survival in the phase 3 COMFORT studies in pts with MF. Here we...
更多查看译文
关键词
myelofibrosis,ruxolitinib,ruxolitinib,long-term
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要